LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease
|ClinicalTrials.gov Identifier: NCT01860118|
Recruitment Status : Completed
First Posted : May 22, 2013
Last Update Posted : April 5, 2017
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||601 participants|
|Official Title:||LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||June 21, 2016|
|Actual Study Completion Date :||June 21, 2016|
1) the presence of bradykinesia and either rest tremor or rigidity; 2) asymmetric onset; 3) progressive motor symptoms 4) age at onset 21-99 years.
Healthy controls between ages of 21-99 years and a lack of PD in first-degree blood relatives
- Biomarkers [ Time Frame: up to 3 years ]Biomarkers associated with Parkinson's disease (PD) susceptibility and/or progression in exosome-proteomes derived from PD patients versus controls.
- LRRK2 expression and/or phosphorylation [ Time Frame: up to 3 years ]Determine if LRRK2 expression and/or phosphorylation are significantly lowered in the exosomes of individuals treated with the potent LRRK2 kinase inhibitor sunitinib (a multi-kinase inhibitor compound), to establish an assay for on-target effects for future LRRK2 inhibitor clinical trials.
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01860118
|United States, Alabama|
|University of Alabama at Birmingham Sparks Center|
|Birmingham, Alabama, United States, 35294|
|Principal Investigator:||Andrew West, PhD||University of Alabama at Birmingham|